TalkMed's (SGX:5G3) attributable profit to owners jumped 90% during the second half of 2024 to SG$34.0 million from SG$17.9 million a year earlier, according to a filing with the Singapore Exchange on Tuesday.
Earnings per share rose to SG$0.0254 compared with SG$0.0134 in the comparable period.
Revenue declined 2% year over year to SG$45.1 million from SG$46.0 million, due to a decrease in revenue from the oncology services segment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.